Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Gracia J, Hodi F, Taus A, Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal For ImmunoTherapy Of Cancer 2022, 10: e004076. PMID: 35577503, PMCID: PMC9114963, DOI: 10.1136/jitc-2021-004076.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungFatigueHumansImmune Checkpoint InhibitorsLigandsLung NeoplasmsMelanomaReceptor Protein-Tyrosine KinasesUrinary Bladder NeoplasmsConceptsNon-small cell lung cancerUrothelial bladder cancerObjective response rateOptimal biological doseImmune checkpoint blockersUBC patientsConfirmed objective response rateTreatment-related adverse eventsCell death 1 ligandPhase 1b studyManageable safety profileImmune checkpoint blockadeCell lung cancerDeath 1 ligandAtezolizumab monotherapyPatients naïveAdverse eventsCheckpoint blockadeCheckpoint blockersNSCLC patientsSkin rashDose escalationClinical benefitSafety profileLung cancer